Phase I, First-in-Human, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of MS201408-0005A as Single Agent and Sequentially in Combinations With MS201408-0005C or MS201408-0005B in Subjects With Metastatic or Locally Advanced Unresectable Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2018
At a glance
- Drugs MS-201408-0005-A-EMD-Serono (Primary) ; MS-201408-0005B-EMD-Serono (Primary) ; MS-201408-0005C-EMD-Serono (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors EMD Serono Research & Development Institute
- 18 Jul 2018 Planned End Date changed from 24 Jan 2020 to 3 Sep 2020.
- 21 Jun 2018 Planned End Date changed from 22 Jun 2018 to 24 Jan 2020.
- 21 Jun 2018 Planned primary completion date changed from 22 Jun 2018 to 18 Dec 2018.